Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $46.5 million.

  • Celldex Therapeutics' Total Current Liabilities rose 4478.24% to $46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year increase of 4478.24%. This contributed to the annual value of $39.5 million for FY2024, which is 2691.08% up from last year.
  • Celldex Therapeutics' Total Current Liabilities amounted to $46.5 million in Q3 2025, which was up 4478.24% from $33.0 million recorded in Q2 2025.
  • Celldex Therapeutics' Total Current Liabilities' 5-year high stood at $46.5 million during Q3 2025, with a 5-year trough of $14.2 million in Q3 2021.
  • In the last 5 years, Celldex Therapeutics' Total Current Liabilities had a median value of $26.3 million in 2024 and averaged $24.7 million.
  • Per our database at Business Quant, Celldex Therapeutics' Total Current Liabilities skyrocketed by 10671.59% in 2022 and then plummeted by 4775.79% in 2023.
  • Over the past 5 years, Celldex Therapeutics' Total Current Liabilities (Quarter) stood at $16.5 million in 2021, then rose by 12.6% to $18.6 million in 2022, then soared by 67.25% to $31.1 million in 2023, then increased by 26.91% to $39.5 million in 2024, then rose by 17.63% to $46.5 million in 2025.
  • Its Total Current Liabilities was $46.5 million in Q3 2025, compared to $33.0 million in Q2 2025 and $32.0 million in Q1 2025.